title: Acute tubular necrosis following interferon-based therapy for hepatitis C: case study with literature review.
abstract: OBJECTIVE
  Interferon treatment of malignant or viral diseases can be accompanied by various side-effects including nephro-toxicity.
  
  
  METHODS
  We report on a 68-year-old Caucasian male who received dual therapy with pegylated interferon 2a plus ribavirin for chronic hepatitis C.
  
  
  RESULTS
  After three months of antiviral therapy, the patient developed acute kidney failure (serum creatinine up to 6 mg/dL) with mild proteinuria (500 mg daily) and haematuria. Immediate immunosuppressive therapy with high-dose intravenous steroids did not improve kidney function. Kidney biopsy was consistent with acute tubular necrosis without glomerular abnormalities. He started long-term peritoneal dialysis (four regular exchanges) to provide both dialysis adequacy and ascites removal. Kidney function gradually improved over the following months (serum creatinine around 2 mg/dL) and peritoneal dialysis was continued with two exchanges daily. The temporal relationship between the administration of the drug and the occurrence of nephro-toxicity, and the absence of other obvious reasons for acute tubular necrosis support a causative role for pegylated interferon; benefit on kidney disease was noted after withdrawal of antiviral agents. An extensive review of the literature on acute tubular necrosis associated with interferon-based therapy, based on in vitro data and earlier case-reports, has been made. The proposed pathogenic mechanisms are reviewed.
  
  
  CONCLUSIONS
  Our case emphasizes the importance of monitoring renal function during treatment of chronic hepatitis C with antiviral combination therapy as treatment may precipitate kidney damage at tubular level.
authors.affiliation: Division of Nephrology, Maggiore Policlinico Hospital, IRCCS Foundation, Milan, Italy.
authors.forename: Fabrizio
authors.initials: F
authors.lastname: Fabrizi
authors.forename: Alessio
authors.initials: A
authors.lastname: Aghemo
authors.forename: G Battista
authors.initials: GB
authors.lastname: Fogazzi
authors.forename: Gabriella
authors.initials: G
authors.lastname: Moroni
authors.forename: Patrizia
authors.initials: P
authors.lastname: Passerini
authors.forename: Roberta
authors.initials: R
authors.lastname: D'Ambrosio
authors.forename: Piergiorgio
authors.initials: P
authors.lastname: Messa
mesh_terms: D000368:Aged; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D006526:Hepatitis C / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use*; D007677:Kidney Function Tests; D007683:Kidney Tubular Necrosis, Acute / Q000139:chemically induced* / Q000150:complications / Q000473:pathology*; D007684:Kidney Tubules / Q000473:pathology; D008297:Male; D014766:Viremia / Q000821:virology
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha